Marzena Pazgier Selected Research

Vaccines

4/2021	Erratum for Tolbert et al., "Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial".
9/2020	Effects of gp120 Inner Domain (ID2) Immunogen Doses on Elicitation of Anti-HIV-1 Functional Fc-Effector Response to C1/C2 (Cluster A) Epitopes in Mice.
1/2020	Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial.
12/2019	Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects.
1/2019	Induction of Fc-Mediated Effector Functions Against a Stabilized Inner Domain of HIV-1 gp120 Designed to Selectively Harbor the A32 Epitope Region.
11/2017	Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region.
1/2017	Survivors Remorse: antibody-mediated protection against HIV-1.
1/2016	Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region.
9/2015	Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marzena Pazgier Research Topics

Disease

22	Infections 03/2023 - 01/2007
7	Neoplasms (Cancer) 09/2021 - 09/2008
6	COVID-19 01/2023 - 01/2021
5	Viremia 11/2023 - 09/2015
3	Inflammation (Inflammations) 11/2023 - 01/2007
3	HIV Infections (HIV Infection) 01/2020 - 01/2016
2	Coronary Artery Disease (Coronary Atherosclerosis) 11/2023 - 08/2023
2	Atherosclerotic Plaque (Atheroma) 11/2023 - 08/2023
2	Cardiovascular Diseases (Cardiovascular Disease) 11/2023 - 08/2023
2	Premature Aging 11/2023 - 08/2023
1	Bites and Stings (Sting) 01/2024
1	Disease Progression 01/2020
1	Virus Diseases (Viral Diseases) 12/2019
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 12/2019
1	Reinfection 11/2019
1	Bacillary Dysentery (Shigellosis) 01/2018
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2017
1	Sepsis (Septicemia) 01/2013
1	Glioblastoma (Glioblastoma Multiforme) 08/2010
1	Crohn Disease (Crohn's Disease) 08/2009

Drug/Important Bio-Agent (IBA)

17	AntibodiesIBA 11/2023 - 01/2013
9	VaccinesIBA 04/2021 - 09/2015
7	EpitopesIBA 10/2021 - 01/2016
6	Glycoproteins (Glycoprotein)IBA 03/2024 - 01/2016
6	Neutralizing AntibodiesIBA 01/2022 - 01/2017
4	Peptides (Polypeptides)IBA 09/2021 - 08/2010
4	Tumor Suppressor Protein p53IBA 09/2021 - 04/2010
4	DefensinsIBA 01/2018 - 01/2007
3	Proteins (Proteins, Gene)FDA Link 07/2007 - 01/2007
2	CytokinesIBA 11/2023 - 08/2023
2	piperidineIBA 03/2023 - 01/2023
2	1- (3- (2- hydroxyl- 3- piperidin- 1- yl- propoxy)- phenoxy)- 3- piperidin- 1- ylpropan- 2- olIBA 07/2022 - 02/2022
2	Antiviral Agents (Antivirals)IBA 01/2019 - 02/2016
2	Oncogene Proteins (Oncogene Protein)IBA 07/2012 - 08/2010
1	Interleukin-6 (Interleukin 6)IBA 03/2024
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2024
1	Hematoxylin (Haematoxylon)IBA 01/2024
1	Monoclonal AntibodiesIBA 01/2023
1	AntigensIBA 01/2020
1	AIDSVAXIBA 01/2020
1	Virulence Factors (Pathogenicity Factors)IBA 01/2018
1	Viral ProteinsIBA 01/2017
1	Broadly Neutralizing AntibodiesIBA 01/2017
1	Immunoglobulin G (IgG)IBA 02/2016
1	Fc Receptors (Fc Receptor)IBA 09/2015
1	muramyl- NAc- (pentapeptide)pyrophosphoryl- undecaprenolIBA 01/2013
1	human neutrophil peptide 1IBA 01/2013
1	Muramic Acids (Muramic Acid)IBA 01/2013
1	BAS00127538IBA 01/2013
1	Liposomes (Liposome)IBA 08/2010
1	Antineoplastic Agents (Antineoplastics)IBA 08/2010
1	cyclic arginine-glycine-aspartic acid peptideIBA 08/2010
1	IntegrinsIBA 08/2010
1	Histidine (L-Histidine)FDA Link 08/2009
1	Arginine (L-Arginine)FDA Link 08/2009
1	SurvivinIBA 09/2008
1	alpha-DefensinsIBA 08/2008
1	Amino Acids FDA Link 01/2007

Therapy/Procedure

7	Therapeutics 11/2023 - 03/2009
2	Immunotherapy 07/2022 - 02/2022
1	Art Therapy 08/2023
1	Molecular Targeted Therapy 08/2010